Laxmi Dental Ltd
Laxmi Dental Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
Guidance rank: #10 of 12 in Healthcare Equipment & Supplies
See the sector's top 10 — free with your mobile number.
What the Q1 FY27 call signalled
2 of 4 strong
The short version
Laxmi Dental aims to outperform the industry CAGR in the aligner business, targeting exponential growth beyond the current ~30% CAGR through branding, education, and marketing initiatives (Page 14). Laxmi Dental aims for revenue growth of 15-20% year-on-year, continuing past performance (Page 12).
From Laxmi Dental Ltd's Q1 FY27 earnings-call transcript · updated 28 Aug 2026.
Revenue & Sales Performance
- Laxmi Dental aims to outperform the industry CAGR in the aligner business, targeting exponential growth beyond the current ~30% CAGR through branding, education, and marketing initiatives (Page 14).
- The company expects strong growth momentum in aligners supported by training, education, and technology like iScope for at-home monitoring (Page 10).
- Domestic dental lab business showed 12% y-o-y growth and the company expects acceleration in growth in upcoming quarters Q2, Q3, and Q4 (Pages 9, 11).
- Scanner deployment is planned at 800-1,000 units for the current financial year, with adoption expected to gradually drive growth over the next quarters (Page 11).
2 more points from Laxmi Dental Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Laxmi Dental Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Laxmi Dental plans to invest in new machinery during FY27 to modernize and expand manufacturing capacity, supporting long-term growth and improving operational efficiencies.
- The company has executed a letter of intent to acquire new land in Palghar, Maharashtra, aiming to transition from leased premises to an owned facility to enhance workflow efficiency, cost control, and future scalability.
- Plans to let go of two rented factory facilities and move operations to the new facility to eliminate rental costs, with a phased transition to avoid disruptions.
2 more points from Laxmi Dental Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Healthcare Equipment & Supplies
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Laxmi Dental Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The focus is on strong Q1 FY27 results with highest-ever quarterly revenue, good growth in domestic and international markets, and strategic initiatives.
- Management emphasizes controlling performance factors, margin stability, and growth in dental lab and aligner segments.
- Scanner deployment expected to be 800-1000 units in the current financial year, indicating ongoing demand pipeline.
Laxmi Dental Ltd — Quarterly revenue & net profit
Q1 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹74 Cr, net profit ₹10 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Laxmi Dental's management said in earlier quarters
Others in Healthcare Equipment & Supplies this season
- Nureca Ltd (Q1 FY27)
Revenue from Operations for Q1 FY'27: ₹40.3 Cr . Key investor presentation takeaways from Nureca's Q1 FY27 investor presentation — and how it ranks against sect
- Avience Biomedi. (Q1 FY27)
New manufacturing facility has capacity to support peak revenue of around ₹250–265 crore, subject to product mix and approvals. Key concall takeaways from…
- Fischer Medical (Q1 FY27)
The provided pages of the investor presentation do not contain any specific revenue, sales, or volume figures for the quarter, nor details on year-on-year…
- Molbio Diagnosti (Q1 FY27)
Capacity utilization currently at ~58% for test kits and ~42% for devices; automation capex will double revenue capacity with minimal new investment. Key…
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Equipment & Supplies
on management's own guidance
- Strong growth2
- Strong growth1
- Molbio DiagnostiGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Laxmi Dental Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Laxmi Dental Ltd Q1 FY27 results?
Laxmi Dental aims to outperform the industry CAGR in the aligner business, targeting exponential growth beyond the current ~30% CAGR through branding, education, and marketing initiatives (Page 14). Laxmi Dental aims for revenue growth of 15-20% year-on-year, continuing past performance (Page 12).
What is Laxmi Dental Ltd share price analysis?
Laxmi Dental Ltd currently shows a below-average growth signal. The stock trades at a P/E of 31.4 with a market cap of ₹1,090 Cr. Investors should review the full earnings analysis for detailed insights.
Is Laxmi Dental Ltd planning capital expenditure?
Laxmi Dental plans to invest in new machinery during FY27 to modernize and expand manufacturing capacity, supporting long-term growth and improving operational efficiencies.
Keep Laxmi Dental Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.